U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246070) titled 'Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting' on Sept. 16.
Brief Summary: The primary objective of this clinical study is to evaluate the efficacy and safety of nanocrystalline megestrol acetate combined with a 5-HT3 receptor antagonist for the prophylaxis of nausea and vomiting caused by moderately emetogenic chemotherapy drugs.
The study population consists of gastric adenocarcinoma patients who are scheduled to receive their first course of moderately emetogenic chemotherapy (PD-1/PD-L1 immune checkpoint inhibitors combined with the CAPOX regimen). This study is divided into two phases. The fir...